“FDA approved” means the U.S. Food and Drug Administration has reviewed scientific evidence showing a product is safe and effective for its intended use before it can be sold. This designation applies specifically to prescription drugs, biological products like vaccines, and certain high-risk medical devices. It does not apply to everything the FDA oversees, and that distinction trips up a lot of people.
The phrase carries legal weight. A company cannot market a new prescription drug in the United States without first submitting extensive clinical trial data and receiving formal approval from the FDA. But many products people assume are “FDA approved,” including dietary supplements, most medical devices, and cosmetics, go through entirely different regulatory pathways or no premarket review at all.
What the Approval Process Requires
For a new drug to earn FDA approval, its manufacturer must demonstrate two things: that the drug is safe and that it works. The legal standard is called “substantial evidence of effectiveness,” defined as evidence from adequate and well-controlled clinical investigations conducted by qualified experts. In practice, this means the FDA generally expects results from at least two well-designed clinical trials showing the drug does what it claims to do and that its benefits outweigh its risks. For rare diseases where running multiple large trials isn’t feasible, convincing evidence from a single trial can sometimes be enough.
The process starts long before human testing. A company first conducts laboratory and animal studies to understand how the drug works and whether it’s likely to be safe. If those results are promising, the company files an application to begin testing in people. Human trials then proceed through phases: small early studies focused on safety, followed by larger studies that measure whether the drug actually treats the condition. This entire development process, from lab bench to approval application, typically takes years.
Once the company submits all its evidence, FDA reviewers evaluate the clinical data, weigh the drug’s benefits against its risks, and consider what other treatments already exist for the condition. The review also examines manufacturing quality to ensure the drug can be produced consistently. A standard FDA review targets a decision within about 10 months of accepting an application. Priority reviews, reserved for drugs that offer significant improvements over existing treatments, aim for a six-month timeline.
Drugs vs. Biologics: Two Paths to Approval
Traditional drugs, small molecules like most pills you’d pick up at a pharmacy, go through a New Drug Application. Biological products, which include vaccines, gene therapies, and protein-based treatments, require a Biologics License Application instead. Both result in “FDA approval,” but the biologics pathway has additional requirements because these products are far more complex to manufacture.
Biological products are often large molecules derived from living cells rather than chemical synthesis. Because of that complexity, the FDA monitors production from the earliest stages. A potency test is required for every biologic to confirm the product does what it’s supposed to. Changes to the manufacturing process, equipment, or even the facility where a biologic is made can alter the final product in ways that wouldn’t affect a traditional pill, so those changes may require additional clinical studies to confirm the product still works safely.
Medical Devices: Approved vs. Cleared
This is where the language gets confusing. Most medical devices on the market are not “FDA approved.” They are “FDA cleared,” which is a different and less rigorous process.
The FDA classifies devices into three risk-based categories. Class I devices (tongue depressors, bandages) pose the lowest risk and are subject to basic regulatory controls. Class II devices (powered wheelchairs, pregnancy tests) must go through a process called 510(k) clearance, where the manufacturer demonstrates the device is “substantially equivalent” to one already legally marketed. This is clearance, not approval. The company doesn’t have to prove the device is effective through clinical trials. It just has to show it’s similar enough to something already on the market.
Only Class III devices, the highest-risk category including things like pacemakers and artificial hearts, require premarket approval through a formal application with clinical data. This is the only class of devices that can accurately be called “FDA approved.” So when a company says its device is “FDA approved,” check whether it’s actually been cleared through the 510(k) pathway, which involves a substantially lower burden of proof.
What FDA Approval Does Not Cover
Dietary supplements are the biggest source of confusion. By law, the FDA does not have the authority to approve dietary supplements before they are marketed. The manufacturer is responsible for ensuring its products are safe and accurately labeled, but it does not have to submit evidence of safety or effectiveness to the FDA before selling them. The FDA’s role is limited mostly to enforcement after a product is already on shelves: inspecting manufacturing facilities, investigating complaints, and pulling unsafe products from the market.
If a supplement contains a new dietary ingredient not previously found in the food supply, the manufacturer must notify the FDA. But notification is not approval. The FDA also does not approve the claims on supplement labels, with narrow exceptions for certain health claims that require premarket review. Any supplement labeled “FDA approved” is making a false claim.
Emergency Use Authorization Is Not Approval
During public health emergencies, the FDA can issue an Emergency Use Authorization, which allows a product to be used before it completes the full approval process. The legal threshold is deliberately lower: an EUA requires data supporting safety and effectiveness, while full approval requires data proving it.
The distinction became widely known during the COVID-19 pandemic. The FDA’s EUA guidance for COVID-19 vaccines required a median follow-up of at least two months from Phase 3 trials, a timeline the agency described as the minimum needed for some confidence that protection was more than short-lived. Full approval guidelines called for one to two years of follow-up data. While the efficacy numbers for the authorized vaccines exceeded the 50% threshold the EUA guidelines required, the FDA acknowledged that the short follow-up left important questions unanswered, including how long protection lasted and whether booster doses would be needed.
An EUA is temporary. Products under an EUA are expected to eventually complete the standard approval process or be pulled from the market when the emergency declaration ends.
What Happens After Approval
FDA approval is not the end of oversight. Once a drug reaches the market, the FDA requires or requests additional studies to monitor long-term safety and effectiveness. These fall into two categories: postmarketing requirements, which are legally mandated studies, and postmarketing commitments, which the manufacturer has agreed to conduct voluntarily.
Since the FDA Amendments Act of 2007, the agency has had explicit authority to require drug manufacturers to conduct postmarket safety studies when there are signals of serious risk. These studies can be required to assess a known serious risk, investigate signals of a potential serious risk, or identify unexpected problems that weren’t apparent in the original clinical trials. Clinical trials used for approval typically involve thousands to tens of thousands of people. Rare side effects that occur in one out of every 50,000 or 100,000 patients may only become visible once millions of people are using the drug.
The FDA can also require label changes after approval. Prescription drug labeling must be updated when new information makes the existing label inaccurate or misleading. This is why you sometimes see new warnings or revised dosing information added to drugs that have been on the market for years.
Off-Label Use and Labeling Rules
FDA approval is specific to certain uses. A drug approved to treat epilepsy, for example, is approved only for that indication based on the clinical evidence submitted. Manufacturers are legally prohibited from promoting their products for uses beyond what the FDA has approved. Labeling must be “informative and accurate and neither promotional in tone nor false or misleading,” and no implied claims about a drug’s use can be made without adequate evidence of safety and substantial evidence of effectiveness.
Physicians, however, are free to prescribe approved drugs for unapproved uses. This is called off-label prescribing, and it’s both legal and common. A doctor might prescribe a blood pressure medication for migraines if clinical experience or published research supports that use, even though the drug was never formally approved for that purpose. The FDA regulates the product and the manufacturer’s claims about it, not the practice of medicine.